BRD4-IN-41 is a selective BRD4 inhibitor that targets the acetyl-lysine binding site with an IC50 of 34 nM. In addition to inhibiting BRD4, it also affects multiple kinases, including JAK2, FLT3, and NTRK3, with IC50 values ranging from 0.9 nM to 43 nM. This compound downregulates c-MYC, lowers phosphorylated STAT3 levels, and induces G1 cell cycle arrest and apoptosis, demonstrating significant anti-cancer activity. BRD4-IN-41 is particularly relevant for research on hematological malignancies such as multiple myeloma and acute myeloid leukemia.
BRD4-IN-41 is a selective BRD4 inhibitor that targets the acetyl-lysine binding site with an IC50 of 34 nM. In addition to inhibiting BRD4, it also affects multiple kinases, including JAK2, FLT3, and NTRK3, with IC50 values ranging from 0.9 nM to 43 nM. This compound downregulates c-MYC, lowers phosphorylated STAT3 levels, and induces G1 cell cycle arrest and apoptosis, demonstrating significant anti-cancer activity. BRD4-IN-41 is particularly relevant for research on hematological malignancies such as multiple myeloma and acute myeloid leukemia.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
